Gerresheimer AG/€GXI

05:30
08:40
11:45
14:55
18:00
1D1W1MYTD1Y5YMAX

About Gerresheimer AG

Gerresheimer AG is a prominent player in the healthcare and life sciences industry, specializing in the production of glass and plastic products for pharmaceutical and cosmetic packaging. The company’s key offerings include pharmaceutical vials, prefillable syringes, glass and plastic packaging for drugs, as well as delivery systems for the safe administration of medications. Founded in 1864, Gerresheimer has evolved into a global entity with headquarters in Düsseldorf, Germany, and operates manufacturing sites in Europe, the Americas, and Asia. Its strategic strength lies in a broad product portfolio and advanced technical expertise, enabling it to cater to the stringent requirements of its diverse clientele in the healthcare sector. The company’s comprehensive geographic footprint and commitment to innovation bolster its competitive position in the market.

Ticker

€GXI
Sector

Primary listing

XETRA

Employees

13,616

Gerresheimer AG Metrics

BasicAdvanced
€1.3B
20.04
€1.83
0.77
€0.04
0.11%

Bulls say / Bears say

Despite lowering its revenue outlook, Gerresheimer kept its adjusted EBITDA margin target at roughly 20%, highlighting stable profitability. (Reuters)
The company reiterated its mid-term revenue growth target of 6–9%, showing confidence in its long-term growth prospects despite current setbacks. (Reuters)
Warburg Pincus’s ongoing interest in acquiring Gerresheimer around €90 per share underlines the likelihood of a takeover premium and the attractiveness of the company to private equity. (Reuters)
Financial regulator BaFin has started an audit of Gerresheimer’s 2024 accounts over possible “bill-and-hold” revenue recognition issues, sending the stock to its lowest level in 13 years. (Reuters)
The company has twice lowered its 2025 revenue growth forecast and now expects just 0–2% growth, as sluggish demand for cosmetics and oral liquids weighs on results. (Reuters)
Gerresheimer shares have fallen about 29% so far this year, reflecting ongoing investor unease about the group’s strategy and profitability. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €GXI

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs